Interesting article!
The authors are from StemSight - a Finnish biotechnology company specialising in off-the-shelf regenerative cell therapies to treat corneal blindness. What stood out to me the most is that one of the three authors is none other than our supposedly "retired" CEO, Ross aka The Toss Macdonald.
Turns out, he's now their Chief Commercial Officer.The article discusses how to navigate the decision between in-house and outsourced iPSC therapy development and manufacturing.
LMAO - Ross is still a major shareholder of Cynata. You reckon he might be able to point them in the right direction?
Ann: Cynata Presenting at Advanced Therapies Congress, page-4
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
16.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $37.28M | |||
| Open | High | Low | Value | Volume |
| 17.0¢ | 17.0¢ | 16.0¢ | $29.18K | 176.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 66467 | 16.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.5¢ | 65000 | 1 |
View Market Depth
| Last trade - 15.59pm 25/07/2025 (20 minute delay) ? |
| CYP (ASX) Chart |